Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
1.580
-0.070 (-4.24%)
At close: Mar 28, 2025, 4:00 PM
1.630
+0.050 (3.16%)
After-hours: Mar 28, 2025, 7:07 PM EST
Armata Pharmaceuticals Employees
Armata Pharmaceuticals had 66 employees as of December 31, 2023. The number of employees decreased by 9 or -12.00% compared to the previous year.
Employees
66
Change (1Y)
-9
Growth (1Y)
-12.00%
Revenue / Employee
$78,394
Profits / Employee
-$286,606
Market Cap
57.17M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ARMP News
- 10 days ago - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PRNewsWire
- 18 days ago - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 20 days ago - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces Structural Biology Publication - PRNewsWire